



Announcement Summary

Entity name

CARDIEX LIMITED

Announcement Type

New announcement

Date of this announcement

30/5/2025

The Proposed issue is:

A standard pro rata issue (including non-renounceable or renounceable)

A placement or other type of issue

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

ASX +security code	+Security description	Maximum Number of +securities to be issued
CDX	ORDINARY FULLY PAID	101,515,968

Ex date

3/6/2025

+Record date

4/6/2025

Offer closing date

20/6/2025

Issue date

27/6/2025

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
CDX	ORDINARY FULLY PAID	60,909,580

Proposed +issue date

5/6/2025

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

CARDIEX LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

81113252234

1.3 ASX issuer code

CDX

1.4 The announcement is

New announcement

1.5 Date of this announcement

30/5/2025

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

A placement or other type of issue

1.6a The proposed standard +pro rata issue is:

+ Non-renounceable



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

No

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

CDX : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

If the entity has quoted company options, do the terms entitle option holders to participate on exercise?

No

Details of +securities proposed to be issued

ASX +security code and description

CDX : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

The quantity of additional +securities to be issued

1

For a given quantity of +securities held

4



What will be done with fractional entitlements?	Maximum number of +securities proposed to be issued (subject to rounding)
Fractions rounded up to the next whole number	101,515,968

Offer price details for retail security holders

In what currency will the offer be made?	What is the offer price per +security for the retail offer?
AUD - Australian Dollar	AUD 0.04000

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?
Yes

Describe the limits on over-subscription

- a) No Top-Up Securities will be issued to an Eligible Shareholder that would, if issued, result in them (together with their associates) increasing their voting power in the Company above 20% and
- b) no Top-Up Securities will be issued if their issue would contravene any law or Listing Rule.

Will a scale back be applied if the offer is over-subscribed?
Yes

Describe the scale back arrangements

Subject at all times to the Directors' discretion to scale back applications for Top-Up Securities under the Top-Up Facility.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Part 3C - Timetable

3C.1 +Record date

4/6/2025

3C.2 Ex date

3/6/2025

3C.4 Record date

4/6/2025

3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue

6/6/2025



3C.6 Offer closing date

20/6/2025

3C.7 Last day to extend the offer closing date

17/6/2025

3C.9 Trading in new +securities commences on a deferred settlement basis

23/6/2025

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

27/6/2025

3C.12 Date trading starts on a normal T+2 basis

30/6/2025

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

2/7/2025

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer?

Yes

3E.1a Who is the lead manager/broker?

Joint Lead Managers - Blackpeak Capital (Blackpeak), Stralis Capital Partners (Stralis) and Taylor Collison (TC)

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% of Gross Proceeds with exceptions. Gross Proceeds refers to the total amount raised under the Offer.

3E.2 Is the proposed offer to be underwritten?

Yes

3E.2a Who are the underwriter(s)?

Blackpeak are sole underwriter of the Entitlement Offer, (with C2 Ventures Pty Limited partially sub-underwriting the Entitlement Offer).

3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?

Fully Underwritten

3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?

6% of Gross Proceeds with exceptions. This fee is part of and not in addition to the fee listed at 3E.1b.

3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated

Refer to the termination events in the investor presentation released to the ASX on 30 May 2025.

3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?

Yes

3E.2e (i) What is the name of that party?

C2 Ventures Pty Limited (a Company jointly owned by Directors Niall Cairns and Craig Cooper).



3E.2e (ii) What is the extent of their underwriting or sub-underwriting (ie the amount or proportion of the offer they have underwritten or sub-underwritten)?

To sub-underwrite up to \$1.2 million of the Entitlement Offer in part, subject to compliance with the regulatory requirements.

3E.2e (iii) What fee, commission or other consideration is payable to them for acting as underwriter or sub-underwriter?

None

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

Yes

3E.3a Will the handling fee or commission be Dollar based or Percentage based?

Percentage based (%)

3E.3b Amount of any handling fee or commission payable to brokers who lodge acceptances or renunciations on behalf of eligible security holders

4.000000 %

3E.3c Please provide any other relevant information about the handling fee or commission method

Only on amounts sub-underwritten by TC or firm commitment fees from existing holders introduced and committed via TC.

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Legal, share registry and advisory costs in the ordinary course.

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Funds raised will primarily be applied towards funding the operations of the Company, inventory, sales and Marketing, product development and regulatory, repayment of debt, capital raising costs and for general working capital purposes.

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?

No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

Entitlement Offer will only be made to shareholders with an address in Australia (AUS) and subject to the restrictions in New Zealand, the United Kingdom (UK), Singapore and Hong Kong (HK).

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

Yes

3F.5a Please provide further details of the offer to eligible beneficiaries

See the offer document as lodged with the ASX.

3F.6 URL on the entity's website where investors can download information about the proposed issue

<https://cardiex.com/investors/>

3F.7 Any other information the entity wishes to provide about the proposed issue

None.

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?

No

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)





Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	31/7/2025	Estimated	

Comments

C2 Ventures and director participation in the Placement is subject to shareholder approval to be sought at an upcoming Extraordinary General Meeting.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ASX +security code and description

CDX : ORDINARY FULLY PAID

Number of +securities proposed to be issued

60,909,580

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.04000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?



Yes

Part 7C - Timetable

7C.1 Proposed +issue date

5/6/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

42,500,000 Fully Paid Ordinary Shares

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Joint Lead Managers - Blackpeak Capital, Stralis Capital Partners and Taylor Collison

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% of Gross Proceeds with exceptions. Gross Proceeds refers to the total amount raised under the Offer.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Legal, share registry and advisory costs in the ordinary course.



Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Funds raised will primarily be applied towards funding the operations of the Company, inventory, sales and Marketing, product development and regulatory, repayment of debt, capital raising costs and for general working capital purposes.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

None.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)